One-year longitudinal association between changes in dietary choline or betaine intake association with cardiometabolic variables in the PREDIMED-Plus trial

Choline and betaine intake have been related to cardiovascular health.

We aimed to explore the relationship between 1-year changes in dietary intake of choline or betaine and 1-year changes in cardiometabolic and renal function traits within the frame of the PREDIMED-Plus trial.

We used baseline and 1 year follow-up data from 5,613 participants (48.2% female and 51.8% male, mean age 65.01 ± 4.91) to assess cardiometabolic traits, and 3,367 participants to assess renal function, of the Spanish PREDIMED-Plus (“PREvention with MEDiterranean DIet”) trial. Participants met at least three criteria of metabolic syndrome (MetS) and had overweight or obesity (BMI ≥27 and ≤40kg/m2). These criteria were similar to those of the PREDIMED parent study. Dietary intake of choline and betaine was estimated from the Food Frequency Questionnaire (FFQ).

The greatest one-year increase in dietary choline or betaine intake (Q4) was associated with improved serum glucose (-3.39 and -2.72 mg/dL for choline or betaine, respectively) and glycated hemoglobin levels (-0.10% for Q4 of either choline or betaine intake increase). Other significant changes associated with the greatest increase in choline or betaine intake were: reduced body weight (-2.93 and -2.78 Kg, respectively), BMI (-1.05 and -0.99 Kg/m2, respectively), waist circumference (-3.37 and -3.26 cm, respectively), total cholesterol (-4.74 and -4.52 mg/dL, respectively) and LDL cholesterol (-4.30 and -4.16 mg/dL, respectively). Urine creatinine was reduced in Q4 of one-year increase in choline or betaine intake (-5.42 and -5.74 mg/dL, respectively).

Increase in dietary choline or betaine intake were longitudinally related to improvements in cardiometabolic parameters. Markers of renal function were also slightly improved, and they required further investigation.

Research news tags: